

Tingting Xu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5229585/publications.pdf>

Version: 2024-02-01

27
papers

436
citations

840585

11
h-index

752573

20
g-index

27
all docs

27
docs citations

27
times ranked

764
citing authors

#	ARTICLE	IF	CITATIONS
1	Comprehensive analysis of prognostic value of lymph node staging classifications in patients with head and neck squamous cell carcinoma after cervical lymph node dissection. <i>European Journal of Surgical Oncology</i> , 2021, 47, 1710-1717.	0.5	7
2	Progression-Free Survival Prediction in Patients with Nasopharyngeal Carcinoma after Intensity-Modulated Radiotherapy: Machine Learning vs. Traditional Statistics. <i>Journal of Personalized Medicine</i> , 2021, 11, 787.	1.1	7
3	Survival impact of increasing time to IMRT initiation following induction chemotherapy in nasopharyngeal carcinoma: A propensity score-matched analysis. <i>Oral Oncology</i> , 2021, 122, 105506.	0.8	2
4	Targeting CDK7 suppresses super enhancer-linked inflammatory genes and alleviates CAR T cell-induced cytokine release syndrome. <i>Molecular Cancer</i> , 2021, 20, 5.	7.9	12
5	An open-label, randomized trial of the combination of IFN- β plus TFF2 with standard care in the treatment of patients with moderate COVID-19. <i>EclinicalMedicine</i> , 2020, 27, 100547.	3.2	29
6	Human papillomavirus (HPV) in Chinese oropharyngeal squamous cell carcinoma (OPSCC): A strong predilection for the tonsil. <i>Cancer Medicine</i> , 2020, 9, 6556-6564.	1.3	14
7	Dynamic Changes in Cognitive Function in Patients With Radiation-Induced Temporal Lobe Necrosis After IMRT for Nasopharyngeal Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 450.	1.3	6
8	Radiation therapy-induced reactive oxygen species specifically eliminates CD19 ⁺ AlgA ⁺ AB cells in nasopharyngeal carcinoma. <i>Cancer Management and Research</i> , 2019, Volume 11, 6299-6309.	0.9	6
9	Suggestions for surveillance and radiation strategy in nasopharyngeal carcinoma treated with IMRT: Based on hazard-rate and patterns of recurrence. <i>Oral Oncology</i> , 2018, 76, 61-67.	0.8	11
10	Prognostic values of hematological biomarkers in nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy. <i>European Archives of Oto-Rhino-Laryngology</i> , 2018, 275, 1309-1317.	0.8	20
11	Treatment Outcomes and Prognostic Factors of Adult Sinonasal Sarcomas: A Single-Institution Case Series. <i>Medical Science Monitor</i> , 2018, 24, 6113-6118.	0.5	2
12	Interplay of Tumor Spread, Volume and Epstein-Barr Virus DNA in Nasopharyngeal Carcinoma: Feasibility of An Integrative Risk Stratification Scheme. <i>Journal of Cancer</i> , 2018, 9, 4271-4278.	1.2	7
13	Quantitative Metastatic Lymph Node Regions on Magnetic Resonance Imaging Are Superior to AJCC N Classification for the Prognosis of Nasopharyngeal Carcinoma. <i>Journal of Oncology</i> , 2018, 2018, 1-10.	0.6	16
14	Radiotherapy as salvage treatment of salivary duct carcinoma in major salivary glands without radical operations. <i>Cancer Management and Research</i> , 2018, Volume 10, 6071-6078.	0.9	6
15	Pre-treatment Serum Lactate Dehydrogenase is Predictive of Survival in Patients with Nasopharyngeal Carcinoma Undergoing Intensity-Modulated Radiotherapy. <i>Journal of Cancer</i> , 2018, 9, 54-63.	1.2	11
16	Patterns of local failures and suggestions for reduction of clinical target volume for nasopharyngeal carcinoma patients without cervical lymph node metastasis. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 2545-2555.	1.0	8
17	Prognostic value of inflammation-based prognostic index in patients with nasopharyngeal carcinoma: a propensity score matching study. <i>Cancer Management and Research</i> , 2018, Volume 10, 2785-2797.	0.9	24
18	Prognostic value of nutritional markers in nasopharyngeal carcinoma patients receiving intensity-modulated radiotherapy: a propensity score matching study. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 4857-4868.	1.0	15

#	ARTICLE	IF	CITATIONS
19	Radiation-induced nasopharyngeal ulcers after intensity modulated radiotherapy in primary nasopharyngeal carcinoma patients: A dose-volume-outcome analysis. <i>Oral Oncology</i> , 2018, 84, 1-6.	0.8	9
20	EZH2 suppresses the nucleotide excision repair in nasopharyngeal carcinoma by silencing XPA gene. <i>Molecular Carcinogenesis</i> , 2017, 56, 447-463.	1.3	10
21	Who benefited most from higher cumulative dose of cisplatin among patients with locally advanced nasopharyngeal carcinoma treated by intensity-modulated radiation therapy? A retrospective study of 527 cases. <i>Journal of Cancer</i> , 2017, 8, 2836-2845.	1.2	11
22	Cetuximab in combination with chemoradiotherapy in the treatment of recurrent and/or metastatic nasopharyngeal carcinoma. <i>Anti-Cancer Drugs</i> , 2016, 27, 66-70.	0.7	20
23	The role of adjuvant chemotherapy in nasopharyngeal carcinoma with bulky neck lymph nodes in the era of IMRT. <i>Oncotarget</i> , 2016, 7, 21013-21022.	0.8	19
24	Outcomes of primary mucosal melanoma originated from sinonasal tract. <i>Journal of Radiation Oncology</i> , 2015, 4, 243-247.	0.7	0
25	Omission of Chemotherapy in Early Stage Nasopharyngeal Carcinoma Treated with IMRT. <i>Medicine (United States)</i> , 2015, 94, e1457.	0.4	35
26	Treatment outcomes and late toxicities of 869 patients with nasopharyngeal carcinoma treated with definitive intensity modulated radiation therapy: new insight into the value of total dose of cisplatin and radiation boost. <i>Oncotarget</i> , 2015, 6, 38381-38397.	0.8	78
27	Effect of Dosimetric Factors on Occurrence and Volume of Temporal Lobe Necrosis Following Intensity Modulated Radiation Therapy for Nasopharyngeal Carcinoma: A Case-Control Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 261-269.	0.4	51